Scilex Holding (SCLXW) Non-Current Assets (2020 - 2026)
Scilex Holding (SCLXW) recorded quarterly Non-Current Assets of $1.5 million in Q1 2026, up 196.18% quarter-over-quarter from $523000.0 in Q4 2025, and up 1201.68% on a YoY basis from $119000.0 in Q1 2025.
Scilex Holding (SCLXW) Non-Current Assets (2020 - 2026) Analysis & Trends
Scilex Holding's Non-Current Assets history runs 7 years deep, the most recent figure standing at $1.5 million for Q1 2026.
- In Q1 2026, Non-Current Assets rose 1201.68% year-over-year to $1.5 million; the TTM figure through Mar 2026 stood at $1.5 million (up 1201.68% YoY), while the FY2025 annual figure was $523000.0, up 339.5% from the prior year.
- Non-Current Assets was $1.5 million for Q1 2026 at Scilex Holding, up from $523000.0 in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $141.7 million in Q2 2022 to a low of $119000.0 in Q4 2024.
- Historically, Non-Current Assets has averaged $23.6 million across 5 years, with a median of $944000.0 in 2022.
- The sharpest annual moves came in 2023 and 2024: Non-Current Assets tumbled 99.89% in 2023, then jumped 4814.46% in 2024.
- A 5-year view of Non-Current Assets shows it stood at $944000.0 in 2022, then decreased by 4.98% to $897000.0 in 2023, then slumped by 86.73% to $119000.0 in 2024, then surged by 339.5% to $523000.0 in 2025, then soared by 196.18% to $1.5 million in 2026.
- The last three Non-Current Assets figures came in at $1.5 million (Q1 2026), $523000.0 (Q4 2025), and $119000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | 60.81 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | 61.74 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | 141.72 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | 102.93 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | 125.00 Mn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | 61.03 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 37.64 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | 165.18 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | 59.27 Bn |
| 10 | Scilex Holding | - | - | 4.15 Mn | 1.55 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.55 Mn |
| Dec 31, 2025 | 523,000.00 |
| Sep 30, 2025 | 119,000.00 |
| Jun 30, 2025 | 119,000.00 |
| Mar 31, 2025 | 119,000.00 |
| Dec 31, 2024 | 119,000.00 |
| Sep 30, 2024 | 8.16 Mn |
| Jun 30, 2024 | 2.90 Mn |
| Mar 31, 2024 | 1.08 Mn |
| Dec 31, 2023 | 897,000.00 |
| Sep 30, 2023 | 166,000.00 |
| Jun 30, 2023 | 1.14 Mn |
| Mar 31, 2023 | 153,000.00 |
| Dec 31, 2022 | 944,000.00 |
| Sep 30, 2022 | 101.29 Mn |
| Jun 30, 2022 | 141.69 Mn |
| Mar 31, 2022 | 140.45 Mn |
| Dec 31, 2021 | 538,000.00 |
| Sep 30, 2021 | 139.41 Mn |
| Jun 30, 2021 | 139.41 Mn |